（文章来源：证券日报） 证券日报网讯 1月5日，星昊医药发布公告称，公司于2025年11月13日召开公司2025年第五次临时股东 会，审议并通过《关于减少公司注册资本及修订并办理工商登记的议案》。公司已完成相应的工商变更 登记及公司章程备案手续，并于近日取得了北京经济技术开发区市场监督管理局核发的《营业执照》。 本次工商变更完成后，公司注册资本由12，496.12万元变更为12，483.228万元。除以上变更外，其他工 商登记事项未发生变更。 ...

（文章来源：证券日报） 证券日报网讯 1月5日，星昊医药发布公告称，公司通过股份回购专用证券账户，共回购128，920股， 占回购前公司总股本的比例为0.10%。公司已于2025年12月31日在中国证券登记结算有限责任公司北京 分公司办理完毕上述128，920股回购股份的注销手续。本次回购股份注销完成前，公司股份总额为 124，961，200股，本次回购股份注销完成后，公司股份总额为124，832，280股，公司剩余库存股 939，763股。 ...

Core Viewpoint - The innovative drug concept has seen a significant surge in the market, with several companies experiencing notable stock price increases [1] Group 1: Company Performance - Changchun High-tech has risen over 8% [1] - Xinghao Pharmaceutical and Wanbangde have both increased by over 5% [1] - Other companies such as Tibet Pharmaceutical, Rongchang Bio, Xinlitai, Guangsheng Tang, and Nuocheng Jianhua have also shown upward movement in their stock prices [1]

证券代码：430017 证券简称：星昊医药 公告编号：2025-140 北京星昊医药股份有限公司 2023 年股权激励计划首次授予部分第一个行权期股票期权行权结果 公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、股票期权行权结果 （一）实际行权基本情况 注：上表所示部分合计数与各明细数相加之和在尾数上如有差异，系四舍五入原因所致， 下同。 （三）本次行权结果与可行权情况的差异说明 2023 年股权激励计划首次授予部分第一个行权期股票期权行权结果与可行 权情况存在差异。 2023 年股权激励计划首次授予期权的激励对象中有 1 名因离职不再满足激 励对象资格，所获期权不得行权，共 9,000 份。本次可行权的激励对象合计 68 名，可行权数量为 2,764,500 份。截至本次行权认购缴款期满，有 1 名激励对象 因个人原因自愿放弃行权，涉及 45,000 份，实际行权的激励对象共 67 名，实际 行权数量为 2,673,000 份，其中有 2 名激励对象本次部分行权，放弃股票期权 87,000 ...

Group 1 - The CRO (Contract Research Organization) concept stocks in the A-share market have shown strong performance, with notable gains in several companies [1] - Zhaoyan New Drug approached the daily limit increase with a rise of 9.12%, while other companies like Kailaiying, Nossger, and Kanglong Chemical also saw increases exceeding 5% [1][2] - The total market capitalization of Zhaoyan New Drug is 25.3 billion, and it has achieved a year-to-date increase of 103.06% [2] Group 2 - Kailaiying's stock rose by 5.48%, with a total market capitalization of 38.7 billion and a year-to-date increase of 42.84% [2] - Nossger and Kanglong Chemical experienced increases of 5.44% and 5.19%, respectively, with market capitalizations of 5.631 billion and 55.5 billion [2] - Other companies such as Sunshine Nuohuo and Boteng also reported gains of over 5%, with year-to-date increases of 109.05% and 64.55% respectively [2]

申万宏源证券承销保荐有限责任公司 关于北京星昊医药股份有限公司 2025 年半年度持续督导跟踪报告 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"或"保 荐机构"）作为北京星昊医药股份有限公司（以下简称"星昊医药"或"公司"） 的保荐机构。根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上 市规则》等有关法律法规、规范性文件的规定，对星昊医药进行持续督导，并出 具 2025 年半年度持续督导跟踪报告。 二、发现的问题及采取的措施 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1、信息披露 | 无 | 不适用 | | 2、公司内部制度的建立 | 无 | 不适用 | | 和执行 | | | | 3、股东会董事会运作 | 无 | 不适用 | | 4、控制权变动 | 无 | 不适用 | | 5、募集资金使用 | 无 | 不适用 | | 6、关联交易 | 无 | 不适用 | | 7、对外担保 | 无 | 不适用 | | 8、购买出售资产 | 无 | 不适用 | | 9、对外投资 | 无 | 不适用 | | 10、发行人或者其聘请 的中介机构配合保荐工 ...

Group 1 - The company, Xinghao Pharmaceutical, announced the receipt of a termination notice from the National Medical Products Administration regarding its drug registration application for Oseltamivir Phosphate Oral Disintegrating Tablets [2] - The notice indicates that the company has been granted approval to withdraw its registration application for the mentioned drug [2] - This development may impact the company's product pipeline and future revenue potential in the antiviral segment [2] Group 2 - The withdrawal of the application suggests potential regulatory challenges or strategic shifts within the company [2] - The decision reflects the company's ongoing efforts to align its product offerings with market demands and regulatory requirements [2] - The pharmaceutical industry may see similar trends as companies navigate complex regulatory landscapes [2]

证券代码：430017 证券简称：星昊医药 公告编号：2025-138 北京星昊医药股份有限公司 关于公司撤回药品注册申请的进展公告 北京星昊医药股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局核准签发的《药品注册申请终止通知书》，同意公司撤回磷酸奥司他韦口崩 片注册申请。现将有关信息公告如下： 一、药品基本信息 药品名称：磷酸奥司他韦口崩片 剂型：口崩片 注册分类：2.2 申报内容：国内化药申请生产 受理号：CXHS2400026、CXHS2400027 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 申请人：北京星昊医药股份有限公司 结论：根据《药品注册管理办法》第八十九条以及申请人的撤回申请《关于 撤回磷酸奥司他韦口崩片药品上市注册资料的申请》，同意本品注册申请撤回， 终止注册程序。 二、药品的其他相关情况 磷酸奥司他韦原研产品为罗氏公司开发的磷酸奥司他韦胶囊剂和干混悬剂， 商品名达菲。 公司磷酸奥司他韦口崩片临床用于儿童甲型和乙型流感的治疗和预防。公司 该药品注册申请于 2024 ...

Core Viewpoint - Beijing Xinghao Pharmaceutical Co., Ltd. reported a decline in key financial metrics for the first half of 2025, attributing the decrease in net profit primarily to reduced revenue, increased asset and credit impairment losses, and rising management and R&D expenses [1][2][3]. Financial Performance - As of June 30, 2025, the company achieved approximately 308 million yuan in revenue, with a gross margin of 69%, and a net profit attributable to shareholders of about 41.08 million yuan, reflecting a year-on-year decline of 32.01% in net profit [1][2]. - Revenue decreased by 13.12 million yuan, representing a 4.08% decline compared to the same period last year, largely due to significant price reductions in key products resulting from national procurement policies [1][2]. Impairment and Expenses - The company fully provided for impairment on its long-term equity investment in a subsidiary, resulting in an increase in asset and credit impairment losses [2]. - Management and R&D expenses increased by 9.88% and 5.38% year-on-year, respectively, contributing to the decline in net profit [2]. Product Development and Market Impact - The company withdrew its registration application for the innovative drug Oseltamivir Oral Dispersible Tablets, which is significant for pediatric flu treatment, after investing approximately 26.44 million yuan in its development [3]. - The withdrawal is not expected to have a major impact on current product sales or operations, as the company plans to refine its research and reapply for registration [3][4]. Revenue Breakdown by Product Category - Digestive and metabolic drugs saw a significant revenue increase of 36.69%, attributed to successful procurement bids and expanded hospital coverage [5]. - Other categories, such as neurological drugs and anti-tumor medications, experienced substantial declines in revenue, with decreases of 44.96% and 42.38%, respectively [6].

Core Insights - The company reported a total revenue of 308.28 million yuan for the first half of 2025, representing a year-on-year decrease of 4.08% [1] - The net profit for the same period was 41.08 million yuan, showing a significant decline of 32.01% compared to the previous year [1] Financial Performance - As of June 30, 2025, the total assets of the company amounted to 1.89 billion yuan, which is an increase of 42.44 million yuan from the beginning of the year [1] - The total liabilities reached 331.61 million yuan, reflecting an increase of 23.57 million yuan since the start of the year [1] - The owner's equity stood at 1.56 billion yuan, with an increase of 18.88 million yuan from the beginning of the year [1]